Replies to post #9202 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Enrollment does seem to be taking an inordinate amount of time. The trial was approved a couple of months ago. I've heard the hypothesis that they are delaying enrollment until a deal is in place. I'm not sure why such a delay would appeal to either side, to be honest. They can't do a deal with a few patients enrolled? That wouldn't seem to present any obstacle. But I do believe a deal is coming regardless.

[fbg0316]

This possible "tell" of them dragging out the first patient dosing of the Phase III as an implication that a deal could be looming has been my thesis for recently adding some to my ADXS position to the extent I am maxed out, in addition to a more favorable biotech outlook given some of the policy implications of a Trump Administration, such as the potential tax holiday on US Pharma money parked offshore which should help fuel M&A. At the margin, it should also motivate Astra to strike a deal with ADXS sooner rather than later, knowing that Astra's US competitors will soon have more dry power on hand to compete on the deal front with European competitors.